C-reactive Protein Testing Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 1.80 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
C-reactive Protein Testing Market Analysis
The C-reactive protein (CRP) testing market is projected to register a CAGR of 1.8% during the forecast period (2022-2027).
COVID-19 has had an unprecedented effect on the healthcare and diagnostic industry. For instance, according to the study published in Annals of Clinical Microbiology and Antimicrobials, titled "Plasma CRP level is positively associated with the severity of COVID-19" in May 2020, plasma CRP levels were found to be linked to the severity of COVID-19 pneumonia. The findings could help distinguish mild COVID-19 pneumonia patients from those with moderate to severe COVID-19 pneumonia. This could serve as an early warning sign of serious disease, allowing doctors to better stratify patients for transfer to an intensive care unit. The importance of CRP testing in the COVID-19 infection for the stratification of patients will lead to increased demand for CRP testing, thereby impacting the market growth during the pandemic.
The major factors propelling the growth of the C-reactive protein testing market include the rise in prevalence of inflammatory disorders, diabetes, and cancers; the increasing global incidence of endometriosis in women; the rise in funding for technological advancement in diagnostics; and the rise in adoption of point-of-care devices.
According to the data published by the Center for Disease Control and Prevention and updated in July 2022, there are about 20.1 million adults aged 20 and older in the United States who have coronary artery disease. It also reported that in the United States, every year, about 805,000 people have a heart attack. The rising prevalence of cardiovascular diseases will lead to increased adoption of CRP testing to identify the risk associated with cardiovascular disease, thereby driving the market growth.
Furthermore, the rise in product launches of point-of-care CRP tests is expected to contribute to the growth of the CRP testing market. For instance, in May 2020, ProciseDx filed a 510k for the Procise CRP test. The test is performed utilizing ProciseDx's FRET (Fluorescent Resonance Energy Transfer) Point of Care equipment, which is an inflammatory marker extensively used in gastrointestinal therapy.
Therefore, the rising prevalence of cardiovascular disease and rising product launches for point-of-care CRP testing, among others, are expected to drive the growth of this market over the forecast period. On the other hand, lack of public awareness and the availability of alternative treatments are the factors that are expected to hinder the market's growth.
C-reactive Protein Testing Market Trends
This section covers the major market trends shaping the C-reactive Protein Testing Market according to our research experts:
Enzyme-linked Immunosorbent Assay (ELISA) Segment is Expected to Hold a Significant Share in the Market Over the Forecast Period
The Enzyme-linked Immunosorbent Assay (ELISA) segment is expected to hold a significant share in the C-reactive protein testing market by assay type. Factors such as the rise in the prevalence of cancers; the growth in infections such as COVID-19; the surge in partnerships for the commercialization of ELISA tests; and an upsurge in product launches, among others, are expected to drive the growth of this segment during the forecast period.
According to Globocan 2020, the global cancer burden has risen to 19.3 million cases and 10 million cancer deaths in 2020. As the ELISA test can be a useful technique for detecting cancer early on, there will be increased adoption of these tests for the detection of cancer across the world, thereby driving the segment's growth.
Furthermore, the establishment of the facilities providing the test is also expected to boost the growth of the market. For instance, in June 2021, Trivitron Healthcare launched the mobile laboratory for COVID-19 diagnostics to facilitate COVID-19 diagnostics in urban, rural, and far-flung geographies across India. The indigenous lab provides tests for CLIA/Elisa tests for inflammatory markers like D-Dimer, CRP & IL-6, RT-PCR tests, rapid antigen tests, CLIA/Elisa Antibodies Tests IgG and IgM, and others.
Therefore, rising product launches, a rise in collaborations, and a rise in the prevalence of cancer are expected to drive the growth of this segment over the forecast period.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same Over the Forecast Period
North America dominated the market with a large revenue share. The factors that are likely to be responsible for the dominance of this segment are the rise in the prevalence of cardiovascular diseases, rising product launches, the presence of established players, technological advancements, and well-established healthcare infrastructure.
In addition, according to the study published in Frontiers in Immunology, titled "How C-Reactive Protein Structural Isoforms With Distinctive Bioactivities Affect Disease Progression" in September 2020 by the Roosevelt University College of Pharmacy, United States, because of the c-reactive protein (CRP) test functional bioactivity as the prototypic acute phase reactant has eluded clear definition for decades, diagnosticians of various conditions and diseases use CRP blood levels as a simple index for ongoing inflammation. Such studies will lead to further adoption of CRP testing for the diagnosis of inflammation in the body.
Furthermore, in October 2020, Nova Biomedical launched the Allegro C-reactive protein (CRP) test for its Allegro capillary blood analyzer for point-of-care (POC) testing in primary care settings. The Allegro and its StatStrip companion meter give 11 clinically necessary tests to assist clinicians in making therapeutic decisions and changes. The increasing product launches for CRP testing in the United States will lead to increased adoption of these tests, which is thereby expected to drive the growth of this market in the United States.
Therefore, the rising prevalence of cardiovascular diseases and rising product launches, among others, are the factors expected to drive the growth of this market in North America.
C-reactive Protein Testing Industry Overview
The C-reactive Protein testing market is fragmented and competitive. Factors such as strategic partnerships between key market players to expand their product portfolios; expansion in research and development; distribution; and management facilities to gain a competitive edge in the market are expected to drive the market's growth. Some of the companies in this market include Abbott Laboratories, Danaher Corporation (Beckman Coulter Inc.), F. Hoffmann-La Roche AG, Merck KGaA, Quest Diagnostics, and Thermo Fisher Scientific Inc., among others.
C-reactive Protein Testing Market Leaders
-
Beckman Coulter Inc. (Danaher Corporation)
-
Laboratory Corporation of America Holdings
-
Abaxis Inc. (Zoetis)
-
Abbott Laboratories
-
F. Hoffmann-La Roche AG
*Disclaimer: Major Players sorted in no particular order
C-reactive Protein Testing Market News
- In July 2022, Swiss MedTech company Bloom Diagnostics launched the Bloom Inflammation Test, which measures and detects the C-Reactive Protein (CRP) in the bloodstream.
- In January 2022, LumiraDx achieved CE mark approval for its C-reactive protein PCR test. It is a compact, portable, fully-automated microfluidic immunoassay test for the quantitative detection of C-reactive protein that takes only four minutes to deliver the result.
C-reactive Protein Testing Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rise in Prevalence of Inflammatory Disorders
- 4.2.2 Increasing Global Incidence of Endometriosis in Women
- 4.2.3 Rise in Funding toward the Technological Advancement in Diagnostics
- 4.2.4 Rise in the Adoption of Point-of-care Devices
-
4.3 Market Restraints
- 4.3.1 Lack of Public Awareness
- 4.3.2 Availability of Alternative Treatments with Higher Accuracies
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Assay Type
- 5.1.1 Enzyme-linked Immunosorbent Assay (ELISA)
- 5.1.2 Chemiluminescence Immunoassay (CLIA)
- 5.1.3 Immunoturbidimetric Assay
- 5.1.4 Other Assay Types
-
5.2 By Application
- 5.2.1 Diabetes
- 5.2.2 Rheumatoid Arthritis
- 5.2.3 Cardiovascular Disease
- 5.2.4 Inflammatory Bowel Disease
- 5.2.5 Cancer
- 5.2.6 Other Applications
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Zoetis (Abaxis Inc.)
- 6.1.2 Abbott Laboratories
- 6.1.3 Danaher Corporation (Beckman Coulter Inc.)
- 6.1.4 F. Hoffmann-La Roche AG
- 6.1.5 Laboratory Corporation of America Holdings
- 6.1.6 Merck KGaA
- 6.1.7 Quest Diagnostics
- 6.1.8 Randox Laboratories Ltd
- 6.1.9 Siemens Healthineers
- 6.1.10 Thermo Fisher Scientific Inc.
- 6.1.11 Getein Biotech, Inc.
- 6.1.12 HORIBA, Ltd
- 6.1.13 Boditech Med Inc.
- 6.1.14 Aidian
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityC-reactive Protein Testing Industry Segmentation
As per the scope of the report, C-reactive protein (CRP) is one of the highly useful markers of inflammation in the body, which is produced by cells in the liver. C-reactive protein tests are blood tests that measure C-reactive protein levels. These proteins are produced by the liver, and their levels increase when there is inflammation in the body. These tests help to identify and keep track of diseases that cause inflammation, such as certain types of cancer, cardiovascular diseases, and arthritis, among others. The C-reactive protein testing market is segmented by Assay Type (Enzyme-linked Immunosorbent Assay (ELISA), Chemiluminescence Immunoassay (CLIA), Immunoturbidimetric Assay, and Other Assay Types), Application (Diabetes, Rheumatoid Arthritis, Cardiovascular Disease, Inflammatory Bowel Disease, Cancer and Other Applications) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Assay Type | Enzyme-linked Immunosorbent Assay (ELISA) | |
| Chemiluminescence Immunoassay (CLIA) | ||
| Immunoturbidimetric Assay | ||
| Other Assay Types | ||
| By Application | Diabetes | |
| Rheumatoid Arthritis | ||
| Cardiovascular Disease | ||
| Inflammatory Bowel Disease | ||
| Cancer | ||
| Other Applications | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
C-reactive Protein Testing Market Research FAQs
What is the current Global C-reactive Protein Testing Market size?
The Global C-reactive Protein Testing Market is projected to register a CAGR of 1.8% during the forecast period (2024-2029)
Who are the key players in Global C-reactive Protein Testing Market?
Beckman Coulter Inc. (Danaher Corporation), Laboratory Corporation of America Holdings, Abaxis Inc. (Zoetis), Abbott Laboratories and F. Hoffmann-La Roche AG are the major companies operating in the Global C-reactive Protein Testing Market.
Which is the fastest growing region in Global C-reactive Protein Testing Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global C-reactive Protein Testing Market?
In 2024, the North America accounts for the largest market share in Global C-reactive Protein Testing Market.
What years does this Global C-reactive Protein Testing Market cover?
The report covers the Global C-reactive Protein Testing Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global C-reactive Protein Testing Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
C-reactive Protein Testing Industry Report
Statistics for the 2024 C-reactive Protein Testing market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. C-reactive Protein Testing analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
